MyOroface, a Biotech Umeå and Uminova Innovation supported company, won 100 000 SEK and ALMI Invests pitch competition at Åre kapitalmarknadsdagar.
The spirits were high as the 17 local biotech companies, national and international investors, industrial partners, sponsors, and speakers had the chance to take the pulse of one another, during partnering and mingle in the guilt-edged surroundings of Grand Hôtel on January 27. This year’s investment event certainly served as a starting point for many interesting discussions.
The spin-off company, and former UBI project, Pro Test Diagnostics AB, have received a step wise investment from Fort Knox Förvaring, to ensure that Pro Test Diagnostics blood doping test reaches the market within three years. The goal is to be able to provide costumers like WADA (World Anti Doping Association) with a fool proof test that can expose blood doped athletes. Something that until now has been lacking.
Biotech, pharma, or medtech? Looking for investors, partners or other new business contacts?
Don't miss the chance to get help from Umeå University’s absolutely sharpest and most ambitious students, who are capable of executing high quality assignments as consultants for your company.
In the middle of November, Uminova Innovation and Biotech Umeå organized a 2-days course for CEO's. The course covered several different topics important for a CEO, such as different legislations, the responsibility towards the board and owners, as well as towards the employees. The seminars were led by Bosse Brixman from Executive People, and the event took place at the Guitar Museum in Umeå.
Umeå spin-off company, Lipigon Pharmaceuticals and AstraZeneca enter a research collaboration to develop a high throughput assay for the identification of molecules against elevated blood lipids.
It has been week to remember, Nordic Biomarker is on a roll. First, the company was awarded the spin-off company of the year at Umeågalan, then they found themselves on Deloitte’s list of the fastest growing tech companies in Sweden.
In a successful study; carried out in collaboration between Pernilla Abrahamsson at MD Biomedical, Senzime, and Umeå University, it is shown that MD Biomedical's microdialysis probe (Onzurf) is able to detect ischemic conditions in the gut. The goal is that the probe shall be used to monitor, and thus be able to prevent complications after surgery.
The onset of the eye disease Glaucoma, can occur at any age, but it becomes more frequent with increasing age. Only half of all patients with Glaucoma are aware of their problems, with a buildup of the fluid pressure in the eye. This is unfortunate since an early discovery, followed by lifelong treatment to reduce the pressure, decrease the risk for loss of eye sight. Alongside the lifelong treatment, follows the need for regular checkups, where the pressure in the eye is monitored.
Umecrine Mood AB announced the final results from an exploratory randomized Phase I/II study with its candidate drug UC1010 in patients with PMDD. The results show a statistically significant improvement of symptoms in patients treated with UC1010 compared to placebo.
Most women experience some form of premenstrual symptoms but in about five percent of young and middle‐aged women that have PMDD, the symptoms are so debilitating that they affect normal daily life, work and relationships. The severity of the symptoms confers huge costs on society.
NLSDAYS 2015. Investment - Partnering - Network
Biotech Umeå, Uminova Innovation
Box 7978, SE-907 19 Umeå